To evaluate the safety and complication of kidney transplantation in seropositive HTLV1 recipients. From December 1998 to September 2005, 536 recipients underwent kidney transplantation in our center. 340 patients were male and 196 female. 510 patients received their graft from living donor and 26 from cadaver. Four recipients (0.74%) were seropositive HTLV1 that entered the study. In 3 patients it was for the first time that and in 1 patient for the second time such procedure was done. Patients were 35-53 years old (mean 42 years). Two patients (50%) were male and 2 were female (50%). Follow-up was done for 5-76 months (mean 30 m.). Blood group in 3 patients was A+ and in one B -. Immuno-suppression therapy consist of cyclosporine, mycophenolate mofetil, prednisolon and cyclosporine, azathioperine and prednisolon were used in 3 and 1 respectively. Any of patients developed ATL after surgery and non of patients had graft dysfunction, graft loss or other complication associated with HTLV1. In one patient (25%) large lymphocele developed that managed by opening a window into the peritoneum with open surgery.Kidney transplantation is safe in HTLV1 seropositive recipients despite relatively long term immunosuppression therapy.